This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hicks, D. G. Articles by Casey, G. Search for Related Content PubMed PubMed Citation Articles by Hicks, D. G. Articles by Casey, G.

Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients

Authors' Affiliations: ¹ Departments of Clinical and Anatomic Pathology, ² General Surgery-Breast Center, and ³ Hematology and Oncology, and ⁴ Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio; ⁵ Roswell Park Cancer Research Institute, Buffalo, New York; and ⁶ Department of Pathology and Comprehensive Cancer Center, The University of Alabama, Birmingham, Alabama

Requests for reprints: Graham Casey, Department of Cancer Biology, ND50, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-445-9754; Fax: 216-445-0610; E-mail: caseyg{at}ccf.org.

Purpose: This study aims to determine the effect of loss of breast cancer metastasis suppressor 1 (BRMS1) protein expression on disease-free survival in breast cancer patients stratified by estrogen receptor (ER), progesterone receptor (PR), or HER2 status, and to determine whether loss of BRMS1 protein expression correlated with genomic copy number changes.

Experimental Design: A tissue microarray immunohistochemical analysis was done on tumors of 238 newly diagnosed breast cancer patients who underwent surgery at the Cleveland Clinic between January 1, 1995 and December 31, 1996, and a comparison was made with 5-year clinical follow-up data. Genomic copy number changes were determined by array-based comparative genomic hybridization in 47 breast cancer cases from this population and compared with BRMS1 staining.

Results: BRMS1 protein expression was lost in nearly 25% of cases. Patients with tumors that were PR negative (P = 0.006) or HER2 positive (P = 0.039) and <50 years old at diagnosis (P = 0.02) were more likely to be BRMS1 negative. No overall correlation between BRMS1 staining and disease-free survival was observed. A significant correlation, however, was seen between loss of BRMS1 protein expression and reduced disease-free survival when stratified by either loss of ER (P = 0.008) or PR (P = 0.029) or HER2 overexpression (P = 0.026). Overall, there was poor correlation between BRMS1 protein staining and copy number status.

Conclusions: These data suggest a mechanistic relationship between BRMS1 expression, hormone receptor status, and HER2 growth factor. BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors.

This article has been cited by other articles:

				D. R. Hurst, Y. Xie, K. S. Vaidya, A. Mehta, B. P. Moore, M. A. Accavitti-Loper, R. S. Samant, R. Saxena, A. C. Silveira, and D. R. Welch Alterations of BRMS1-ARID4A Interaction Modify Gene Expression but Still Suppress Metastasis in Human Breast Cancer Cells J. Biol. Chem., March 21, 2008; 283(12): 7438 - 7444. [Abstract] [Full Text] [PDF]

				P. A. Phadke, K. S. Vaidya, K. T. Nash, D. R. Hurst, and D. R. Welch BRMS1 Suppresses Breast Cancer Experimental Metastasis to Multiple Organs by Inhibiting Several Steps of the Metastatic Process Am. J. Pathol., March 1, 2008; 172(3): 809 - 817. [Abstract] [Full Text] [PDF]